Glenmark Pharmaceuticals reported a 930% jump in Q1 net profit to ₹483 crore, driven by a 23% revenue increase. Growth was supported by robust performance in its North American and Indian markets, alongside improved operational margins. Investors will focus on the sustainability of these margins and the pace of new product launches in the US.
Glenmark Pharmaceuticals Limited reported a strong start to the new financial year, with a 930% jump in its consolidated net profit to ₹483 crore for the quarter ended June 30, 2026. This compares to a profit of ₹47 crore in the same period last year. Total revenue for the quarter grew by 23% year-on-year to ₹4,018 crore, reflecting broad-based growth across the company's international and domestic business segments.
Operational Efficiency and Margin Growth
The company’s operational performance showed marked improvement, with earnings before interest, taxes, depreciation, and amortisation (EBITDA) reaching ₹805 crore, a 39% increase from the previous year. The EBITDA margin expanded to 20% from 17.8%, suggesting that the company is managing its input costs and operational expenses more effectively. This improvement is a key metric for investors, as pharmaceutical companies often face pressure on margins due to fluctuations in raw material costs and intense competition in the generic drug space.
Segment Performance in India and North America
The India formulation business saw revenue rise by 15.5% to ₹1,432.1 crore. Secondary sales, which track demand at the pharmacy level, grew by 18.1%, outperforming the broader Indian Pharmaceutical Market's growth rate of 12.2% according to industry data. This growth was driven by key segments including Respiratory, Dermatology, and Cardiac therapies.
In North America, revenue surged by 41.1% to ₹1,097.4 crore. After adjusting for deferred out-licensing income, the core business grew by 19.8%. The company’s ability to scale in the US market was aided by the launch of nine new products during the quarter. The commercial performance of its respiratory drug, RYALTRIS, remains a central factor for the company's international strategy, with the product now marketed in 57 countries.
Global Expansion and Future Outlook
Beyond India and the US, Glenmark reported revenue growth of 11.9% in Europe and 27.7% in emerging markets, including Russia, the CIS region, Latin America, and the Middle East. The consumer care segment also contributed to the results, with the CANDID brand witnessing revenue growth exceeding 30%.
While the current results show significant growth, investors may monitor the company’s ability to maintain these margin levels and manage the risks associated with global regulatory approvals. The company has several abbreviated new drug applications (ANDAs) pending, and the timing of these approvals will influence revenue growth in subsequent quarters. Additionally, because the company operates in multiple geographies, it remains subject to currency risks and changes in international drug pricing policies. The primary monitorable for investors in the coming months will be the progress of new product launches and the continued market penetration of the RYALTRIS portfolio in new territories like Brazil and China.